Une étude de JNJ-80948543, un anticorps de redirection des lymphocytes T, dans le lymphome non hodgkinien (LNH) et la leucémie lymphoïde chronique (LLC)
Une étude de phase 1, première chez l'homme, de JNJ-80948543, un anticorps de redirection des lymphocytes T, chez des participants atteints de LNH et de LLC
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Macquarie University, Australie, 2109
- Macquarie University Hospital
-
Melbourne, Australie, 3004
- The Alfred Hospital
-
Nedlands, Australie, 6009
- Linear Clinical Research Ltd
-
Randwick, Australie, 2031
- Scientia Clinical Research
-
-
-
-
-
Chongqing, Chine, 400044
- Chongqing University Cancer Hospital
-
Guangzhou, Chine, 510060
- Sun Yat Sen University Cancer Center
-
Tianjin, Chine, 300060
- Tianjin cancer hospital
-
Wuhan, Chine, 430030
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
-
-
-
-
Copenhagen, Danemark, 2100
- Rigshospitalet
-
Odense, Danemark, 5000
- Odense University Hospital
-
-
-
-
-
Lille, France, 59037
- CHRU de Lille Hopital Claude Huriez
-
Paris, France, 75005
- Institut Curie
-
Strasbourg, France, 67033
- Institut de Cancerologie Strasbourg Europe ICANS
-
Toulouse, France, 31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Haifa, Israël, 34362
- Carmel Medical Center
-
Jerusalem, Israël, 9112001
- Hadassah Medical Center
-
Tel Aviv, Israël, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Kashiwa, Japon, 277 8577
- National Cancer Center Hospital East
-
Nagoya, Japon, 464 8681
- Aichi Cancer Center
-
Tokyo, Japon, 135 8550
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Gdansk, Pologne, 80 214
- Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
-
Skorzewo, Pologne, 60-185
- Aidport Sp z o o
-
-
-
-
California
-
Duarte, California, États-Unis, 91010
- City of Hope
-
-
New York
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- The University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, États-Unis, 78229
- Texas Transplant Institute
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Seattle Cancer Care Alliance
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologic documentation of disease: B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) requiring therapy.
All participants must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator's judgment.
B-cell NHL as defined per the 2016 world health organization (WHO) classification. In addition, the following disease-specific criteria outlined below must be met:
If diffuse large B-cell lymphoma (DLBCL) or other high-Grade B-cell lymphoma: Received, or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent or deemed not eligible or fit for an alternative 2nd line therapy. Participants may be eligible if relapsing after chimeric antigen receptors (CAR-T) cell treatment or while waiting for a CAR-T cell treatment.
If transformed lymphoma from low Grade B-cell malignancies: Received or not a candidate for an approved first-line regimen for DLBCL and received or not eligible for high-dose chemotherapy and autologous stem cell transplantation with curative intent.
If follicular lymphoma (FL) (all grades): Previously treated with a minimum of 2 prior lines of systemic therapy, with at least one prior line containing an anti-CD20 antibody.
If mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) (including nodal, extranodal/MALT, and splenic MZL subtypes): Previously treated with at least 2 lines of systemic therapy. H.pylori-positive gastric MALT lymphoma must have failed prior H. pylori eradication therapy as one of their prior lines .
Waldenstrom macroglobulinemia (WM): Previously treated with at least 1 line of systemic therapy.
small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL): Relapsed or refractory with at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTK) inhibitor or a BCL2 inhibitor, if eligible. In addition for part B Participants must have measurable disease as defined by the appropriate disease response criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1
- Cardiac parameters within the following range: corrected QT interval (QTc intervals corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480 milliseconds based on the average of triplicate assessments performed no more than 5 (plus minus [+-] 3) minutes apart
- A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta- human chorionic gonadotropin) at screening and must agree to further serum or urine pregnancy tests prior to the first dose, during the study and until 3 months after the last dose of study treatment
- A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment
Exclusion Criteria:
- Known active central nervous system (CNS) involvement; Lymphoma with CNS involvement may be allowed in pharmacokinetic/ pharmacodynamic (PK/PD) and expansion cohorts if approved by the study evaluation team (SET)
- Prior solid-organ transplantation
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
- Clinically significant pulmonary compromise, particularly the need for supplemental oxygen use to maintain adequate oxygenation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part A: Dose Escalation
Participants will receive JNJ-80948543 either by subcutaneous (SC) or intravenous (IV) administration to determine the putative recommended Phase 2 dose (RP2D) dosing schedule(s) and route(s) of administration based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. |
JNJ-80948543 will be administered as SC or IV injection. |
|
Expérimental: Part B: Cohort Expansion
Participants will receive JNJ-80948543 by SC or IV administration. |
JNJ-80948543 will be administered as SC or IV injection. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Dose-limiting Toxicity (DLT)
Délai: Up to 4 Years 3 months
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 4 Years 3 months
|
|
Number of Participants with Adverse Events (AEs)
Délai: Up to 4 Years 3 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to 4 Years 3 months
|
|
Number of Participants with AE by Severity
Délai: Up to 4 Years 3 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 4 (Life-threatening). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded as per American Society for Transplantation and Cellular Therapy (ASTCT). |
Up to 4 Years 3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum Concentration of JNJ-80948543
Délai: Up to 4 Years 3 months
|
Serum samples will be analyzed to determine concentrations of JNJ-80948543 using a validated, specific, and sensitive method. |
Up to 4 Years 3 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543
Délai: Up to 4 Years 3 months
|
Number of participants with presence of anti-drug antibodies of JNJ-80948543 will be assessed. |
Up to 4 Years 3 months
|
|
Overall Response Rate (ORR)
Délai: Up to 4 Years 3 months
|
ORR is defined as the percentage of participants who have a best response of partial response (PR) or better. |
Up to 4 Years 3 months
|
|
Complete Response (CR) Rate
Délai: Up to 4 Years 3 months
|
CR rate is defined as the percentage of participants who achieve a best response of CR. |
Up to 4 Years 3 months
|
|
Rate of VGPR or Better for Participants with Waldenstrom Macroglobulinemia (WM)
Délai: Up to 4 Years 3 months
|
The response criteria planned to be used for participants with WM includes a category of VGPR, which is clinically understood to be better than PR but not as good as CR. For participants with WM, this rate is defined as the proportion of participants who achieve a best response of VGPR or better. |
Up to 4 Years 3 months
|
|
Time to Response (TTR)
Délai: Up to 4 Years 3 months
|
TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR. |
Up to 4 Years 3 months
|
|
Duration of Response (DOR)
Délai: Up to 4 Years 3 months
|
DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death. |
Up to 4 Years 3 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Leucémie, cellule B
- Lymphome
- Leucémie, Lymphoïde
- Leucémie
- Conditions pathologiques, signes et symptômes
- Maladies hémiques et lymphatiques
- Leucémie lymphocytaire chronique à cellules B
- Lymphome non hodgkinien
Autres numéros d'identification d'étude
- CR109174
- 2022-000685-18 (Numéro EudraCT)
- 80948543LYM1001 (Autre identifiant: Janssen Research & Development, LLC)
- 2023-504187-42-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .